Atlas Trials

Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy

Clinical trial NCT04579133 · TERMINATED

Trial details

NCT number
NCT04579133
Sponsor
Latin American Cooperative Oncology Group
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder CancerUrothelial Carcinoma
Start date
2021-03-01
Primary completion
2021-03-01
Enrollment
140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.